{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitazoxanide+%28NTZ%29&page=2", "query": { "intervention": "Nitazoxanide (NTZ)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitazoxanide+%28NTZ%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitazoxanide+%28NTZ%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T13:48:03.060Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00991289", "title": "Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "Hepatitis C Infection" ], "interventions": [ { "name": "Nitazoxanide (NTZ)", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a (PEG)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2010-01", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991289" }, { "nct_id": "NCT00384527", "title": "Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridium Infections" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2006-12", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 10, "location_summary": "Torrance, California • Bay Pines, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384527" }, { "nct_id": "NCT04489381", "title": "Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Enterovirus", "Rhinovirus" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vitamin Super B-Complex", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 214, "start_date": "2020-08-19", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 3, "location_summary": "Hot Springs, Arkansas • Fort Lauderdale, Florida • The Bronx, New York", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04489381" }, { "nct_id": "NCT04343248", "title": "Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "Viral Respiratory Illnesses" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vitamin Super B-Complex", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "55 Years to 120 Years" }, "enrollment_count": 190, "start_date": "2020-05-12", "completion_date": "2021-02-01", "has_results": true, "last_update_posted_date": "2024-07-08", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 4, "location_summary": "Kissimmee, Florida • Acworth, Georgia • Lake Charles, Louisiana + 1 more", "locations": [ { "city": "Kissimmee", "state": "Florida" }, { "city": "Acworth", "state": "Georgia" }, { "city": "Lake Charles", "state": "Louisiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04343248" }, { "nct_id": "NCT05368935", "title": "Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment", "Renal Disease", "Kidney Disease" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genfit", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 77, "start_date": "2022-04-25", "completion_date": "2022-09-09", "has_results": false, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 2, "location_summary": "Miami Lakes, Florida • Orlando, Florida", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05368935" }, { "nct_id": "NCT00004986", "title": "Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cryptosporidiosis", "HIV Infections" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 30, "start_date": "2000-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004986" }, { "nct_id": "NCT00495391", "title": "Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2007-07", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 10, "location_summary": "Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00495391" }, { "nct_id": "NCT04605588", "title": "A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV Infection", "Covid19" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo Nitazoxanide", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo Ribavirin", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 7, "start_date": "2020-12-02", "completion_date": "2021-02-04", "has_results": true, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04605588" }, { "nct_id": "NCT07110441", "title": "Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute-on-Chronic Liver Failure" ], "interventions": [ { "name": "Single Dose G1090N", "type": "DRUG" }, { "name": "Multiple dosing of G1090N", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genfit", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2025-08-26", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07110441" }, { "nct_id": "NCT03336619", "title": "A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1030, "start_date": "2018-01-17", "completion_date": "2019-04-17", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-10-04T13:48:03.060Z", "location_count": 34, "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 28 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Pelham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336619" } ] }